TLDR People with ankylosing spondylitis in Taiwan don't have a higher chance of getting alopecia.
The population-based cohort study, which analyzed data from over 1,000,000 patients in the Taiwan Longitudinal Health Insurance Database, found no increased risk of alopecia in patients with ankylosing spondylitis (AS). The study included 3,640 AS patients and 14,560 non-AS controls. The results showed no significant increase in alopecia risk in AS patients (crude HR 1.16, P = 0.595; adjusted HR 1.16, P = 0.599), even in subgroup analysis of different age, sex, and phenotypes of alopecia. However, a significant positive correlation was found between atopic dermatitis and alopecia (adjusted HR 8.05, P = 0.039).
37 citations,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
176 citations,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
16 citations,
April 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” A patient lost all their hair while on rheumatoid arthritis medication.
61 citations,
June 2010 in “Journal of the European Academy of Dermatology and Venereology” Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.
41 citations,
July 2009 in “International Journal of Trichology” 58% of men aged 30-50 have hair loss, with severity increasing with age.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
12 citations,
March 2023 in “Frontiers in immunology” Atopic dermatitis increases the risk of some autoimmune diseases.
27 citations,
March 2018 in “Allergy and asthma proceedings” People with alopecia areata often have higher rates of allergies and autoimmune diseases.
43 citations,
June 2018 in “Clinics in dermatology” People with atopic dermatitis are more likely to develop other skin conditions due to shared genetics and immune pathways.
